Compare Stocks

→ The only accurate crypto trading system I know … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$65.48 +1.4%	$64.95	$36.99 ▼ $70.81	$1.38B	0.79	139,655 shs	207,268 shs
APRE Aprea Therapeutics	$5.41 -3.6%	$6.47	$2.78 ▼ $8.85	$29.38M	1.03	30,471 shs	7,280 shs
FIXX Homology Medicines		$0.49	$0.46 ▼ $1.48	$54.33M	-0.1	390,307 shs	401,400 shs
RTRX Travere Therapeutics	$5.72 -1.4%	$26.56	$8.98 ▼ $24.96	$292.02M	0.67	412,277 shs	946,701 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	-1.37%	-5.18%	-4.85%	+16.55%	+64.49%
APRE Aprea Therapeutics	+1.92%	-1.02%	-13.35%	+8.35%	+43.84%
FIXX Homology Medicines	0.00%	0.00%	+107.66%	+219.23%	+81.50%
RTRX Travere Therapeutics	-3.17%	-13.30%	-22.46%	-33.64%	-72.78%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIP ANI Pharmaceuticals	4.7164 of 5 stars	2.5	5.0	0.0	3.3	2.5	3.3	3.1
APRE Aprea Therapeutics	3.2007 of 5 stars	3.5	5.0	0.0	0.0	1.7	3.3	0.6
FIXX Homology Medicines	1.5034 of 5 stars	3.3	0.0	0.0	4.8	0.0	0.8	0.6
RTRX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	3.00	Buy	$80.00	22.17% Upside
APRE Aprea Therapeutics	3.00	Buy	$15.50	186.51% Upside
FIXX Homology Medicines	2.50	Moderate Buy	$0.75	∞ Upside
RTRX Travere Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ANIP, RTRX, APRE, and FIXX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/27/2024	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$9.00 ➝ $11.00
3/26/2024	APRE Aprea Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
3/15/2024	ANIP ANI Pharmaceuticals	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$80.00
3/5/2024	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $77.00
3/4/2024	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $83.00
3/1/2024	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $80.00
2/16/2024	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $72.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$486.82M	2.84	$6.42 per share	10.20	$21.13 per share	3.10
APRE Aprea Therapeutics	$580K	50.65	N/A	N/A	$4.54 per share	1.19
FIXX Homology Medicines	$1.16M	0.00	N/A	N/A	$1.26 per share	0.00
RTRX Travere Therapeutics	$175.34M	1.67	N/A	N/A	$5.15 per share	1.11

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	$18.78M	$0.84	77.95	15.82	N/A	3.86%	18.06%	8.38%	5/10/2024 (Confirmed)
APRE Aprea Therapeutics	-$14.29M	-$3.99	N/A	N/A	N/A	N/A	-65.58%	-52.37%	5/20/2024 (Estimated)
FIXX Homology Medicines	-$112.96M	-$1.96	N/A	N/A	N/A	-4,779.31%	-102.52%	-74.91%	5/9/2024 (Estimated)
RTRX Travere Therapeutics	-$146.43M	-$3.46	N/A	N/A	N/A	-49.13%	-36.38%	-14.90%	N/A

Latest ANIP, RTRX, APRE, and FIXX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/10/2024	N/A	ANIP ANI Pharmaceuticals	$0.9650	N/A	-$0.9650	N/A	N/A	N/A
3/26/2024	Q4 2023	APRE Aprea Therapeutics	-$0.56	-$0.92	-$0.36	-$0.92	$0.33 million	$0.01 million
2/29/2024	Q4 2023	ANIP ANI Pharmaceuticals	$0.58	$0.78	+$0.20	$1.52	$123.02 million	$131.65 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
FIXX Homology Medicines	N/A	N/A	N/A	N/A	N/A
RTRX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	0.66	3.57	2.81
APRE Aprea Therapeutics	N/A	5.13	5.13
FIXX Homology Medicines	N/A	7.25	7.25
RTRX Travere Therapeutics	0.66	7.23	7.14

Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
APRE Aprea Therapeutics	34.19%
FIXX Homology Medicines	31.32%
RTRX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	12.70%
APRE Aprea Therapeutics	20.90%
FIXX Homology Medicines	16.10%
RTRX Travere Therapeutics	4.63%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	642	21.08 million	18.40 million	Optionable
APRE Aprea Therapeutics	9	5.43 million	4.30 million	No Data
FIXX Homology Medicines	7	58.13 million	48.77 million	Optionable
RTRX Travere Therapeutics	221	51.05 million	N/A	Not Optionable

ANIP, RTRX, APRE, and FIXX Headlines

Source	Headline
	Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know markets.businessinsider.com - April 17 at 4:04 PM
	Travere Therapeutics price target lowered by $3 at H.C. Wainwright, here's why realmoney.thestreet.com - February 23 at 3:07 PM
	Travere Therapeutics gains as EU backs kidney disease therapy msn.com - February 23 at 8:37 AM
	New Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest? msn.com - February 21 at 8:05 AM
	Travere Therapeutics price target raised by $4 at Citi, here's why realmoney.thestreet.com - February 17 at 7:51 AM
	Travere Therapeutics: Hold Rating Amidst Filspari’s Steady Performance and Emerging Market Competition markets.businessinsider.com - February 16 at 10:57 AM
	Earnings Preview For Travere Therapeutics benzinga.com - February 14 at 4:00 PM
	Travere Therapeutics: A Strong Buy on Filspari’s Outperformance and Promising Market Prospects markets.businessinsider.com - January 11 at 7:54 AM
	Optimistic Outlook for Travere Therapeutics Amid FDA Developments and Strategic Reorganization markets.businessinsider.com - December 7 at 5:53 PM
	Travere (TVTX) Up on Latest Portfolio Updates & Reorganization msn.com - December 6 at 5:04 PM
	Buy Rating for Travere Therapeutics: Optimism Fueled by Regulatory Prospects and Strategic Reorganization markets.businessinsider.com - December 5 at 8:07 PM
	Travere Therapeutics upgraded to Buy from Neutral at Citi realmoney.thestreet.com - December 5 at 2:51 PM
	Travere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU Treatments marketwatch.com - December 4 at 8:55 PM
	Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference benzinga.com - November 21 at 6:25 PM
	Promising Sales Performance and Growth Prospects Solidify Buy Rating for Travere Therapeutics markets.businessinsider.com - November 8 at 3:32 PM
	Preview: Travere Therapeutics's Earnings benzinga.com - November 6 at 2:56 PM
	Travere Therapeutics Inc Ordinary Shares TVTX morningstar.com - October 31 at 6:21 PM
	Wedbush Reiterates Travere Therapeutics (TVTX) Outperform Recommendation msn.com - September 30 at 10:26 AM
	Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Low msn.com - September 22 at 5:07 PM
	Why Shares of Travere Therapeutics Are Slumping Thursday msn.com - September 21 at 3:15 PM
	Back To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challenges markets.businessinsider.com - September 21 at 3:15 PM
	Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX) markets.businessinsider.com - August 31 at 7:43 AM
	Mirum Pharmaceuticals to Buy Bile Acid Product Portfolio from Travere Therapeutics marketwatch.com - July 19 at 8:02 PM
	TVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities Laws benzinga.com - June 26 at 8:57 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ANI Pharmaceuticals

NASDAQ:ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Aprea Therapeutics

NASDAQ:APRE

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Homology Medicines

NASDAQ:FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Travere Therapeutics

NASDAQ:RTRX

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial